**Claims:**

1. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for prophylaxis or treatment of a condition responsive thereto in a subject with at least moderate renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

2. The use according to claim 1 wherein the subject has previously been treated with teduglutide at an adjusted dose.

3. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for prophylaxis or treatment of a condition responsive thereto in a subject for whom an adjusted dose of teduglutide would be indicated as a result of renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

4. The use according to claim 3 wherein said subject has previously have been treated with teduglutide at an adjusted dose.

5. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for prophylaxis or treatment of a condition responsive thereto in a subject who has received an adjusted dose of teduglutide due to renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

6. The use according to any one of claims 1 to 5 wherein the subject has moderate renal impairment, severe renal impairment, or end stage renal disease (ESRD).

7. The use according to any one of claims 1 to 6 wherein the condition to be treated is a stomach or bowel-related disorder.

8. The use according to claim 7 wherein said stomach or bowel related disorder is ulcers, a digestion disorder, a malabsorption syndrome, short-gut syndrome, inflammatory bowel disease, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), ulcerative colitis, small intestine damage or short bowel syndrome (SBS).

9. The use according to claim 8 wherein the condition is short bowel syndrome (SBS)

in a subject receiving parenteral support (PS).

10. The use according to claim 7 wherein the condition is radiation enteritis, infectious or post-infectious enteritis, or small intestinal damage due to toxic or other chemotherapeutic agents.

11. The use according to claim 7 wherein the condition is a side effect of chemotherapy or radiation treatment in a human subject.

12. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for increasing intestinal mass and/or promoting or increasing longitudinal intestinal growth in a subject with at least moderate renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

13. The use according to claim 12 wherein the subject has previously been treated with teduglutide at an adjusted dose.

14. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for increasing intestinal mass and/or promoting or increasing longitudinal intestinal growth in a subject for whom an adjusted dose of teduglutide would be indicated as a result of renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

15. The use according to claim 14 wherein the subject has previously been treated with teduglutide at an adjusted dose.

16. Use of ZP1848 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for increasing intestinal mass and/or promoting or increasing longitudinal intestinal growth in a subject who has received an adjusted dose of teduglutide due to renal impairment, wherein no dose adjustment of ZP1848 or said salt is required.

17. The use according to any one of claims 12 to 16 wherein the subject has moderate renal impairment, severe renal impairment, or ESRD.

18. The use according to any one of claims 12 to 17 wherein the the subject is affected by short bowel syndrome (SBS) and optionally is receiving parenteral support.

19. The use according to any one of claims 1 to 18 wherein said ZP1848 or pharmaceutically acceptable salt is for administration via a dosing regime comprising a plurality or course of doses separated in time by 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days or 12 days, e.g. separated in time by 3 days, 3.5 days, 4 days, 5 days, 6 days, 7 days or 8 days, e.g. separated in time by 3 days, 3.5 days, 4 days or 7 days.

20. The use according to claim 19 wherein said dosing regime is a once or twice weekly dosing regime.

21. The use according to any one of claims 1 to 20 wherein each individual unadjusted dose is between 1 mg and 20 mg inclusive per subject per dose, e.g. between 5 mg and 15 mg, between 7 mg and 12 mg, or between 9 mg and 11 mg inclusive per subject per dose.

22. The use according to claim 21 wherein each individual unadjusted dose is about 10 mg per subject per dose.

23. A pharmaceutical kit comprising ZP1848 or a pharmaceutically acceptable salt thereof and information that no dose adjustment of ZP1848 is required for subjects having at least moderate renal impairment.

24. A kit according to claim 23 wherein said ZP1848 or pharmaceutically acceptable salt is provided as a pharmaceutical composition, comprising said ZP1848 or salt in combination with a pharmacetically acceptable carrier or excipient.

25. A kit according to claim 23 or claim 24 comprising one or more individual measured doses of ZP1848 or said salt, wherein each said dose is between 1 mg and 20 mg, e.g. between 5 mg and 15 mg, between 7 mg and 12 mg, or between 9 mg and 11 mg.

26. A kit according to claim 25 wherein each individual dose is about 10 mg.

27. A kit according to any one of claims 23 to 26 further comprising one or more chemotherapeutic agents.